Gemcitabine Current Events | Page 5

Gemcitabine Current Events, Gemcitabine News Articles.
Sort By: Most Viewed | Most Recent
Page 5 of 6 | 208 Results
M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from the University of Texas M. D. Anderson Cancer Center. (2009-09-24)

New therapeutic combination to slow resistant sarcomas
Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer. (2014-07-10)

SWOG researchers go digital at ASCO20 Virtual Scientific Program
Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31. (2020-05-18)

Metformin treatment caused cancer stem cell death in pancreatic cancer cell lines
Results of some preclinical trials have shown that low doses of the antidiabetic drug metformin may effectively destroy cancer stem cells, a group of cells that are considered to be responsible for tumor initiation and, because they are resistant to standard chemotherapies, tumor relapse. (2012-06-19)

New cancer vaccine extends progression-free survival in patients with advanced lung cancer
A Phase 2 trial, published online first in the Lancet Oncology, has shown that combining standard platinum-based chemotherapy with the new cancer vaccine TG4010 enhances the effect of chemotherapy and slows down the progression of advanced non-small-cell-lung cancer, the most common type of lung cancer, compared with chemotherapy alone. (2011-10-21)

New trick for 'old' drug brings hope for pancreatic cancer patients
Scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumor and stops it spreading. (2014-08-03)

Lung cancer patients with diabetes show prolonged survival
Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer. (2011-10-17)

Penn researchers uncover novel immune therapy for pancreatic cancer
Researchers at the University of Pennsylvania's Abramson Cancer Center have discovered a novel way of treating pancreatic cancer by activating the immune system to destroy the cancer's scaffolding. The strategy was tested in a small cohort of patients with advanced pancreatic cancer, several of whose tumors shrank substantially. The team believes their findings - and the novel way in which they uncovered them -- could lead to quicker, less expensive cancer drug development. The findings are published in the March 25 issue of Science (2011-03-24)

Newer lung cancer treatments extend survival longer than traditional regimens
Patients with advanced non-small cell lung cancer who are treated with regimens containing paclitaxel and carboplatin survive longer than patients treated with older cisplatin-based regimens or supportive care, a new study finds. (2002-06-27)

Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer
For patients with locally advanced pancreatic cancer, the combination of chemotherapy and stereotactic ablative radiation may be a promising treatment option, ultimately allowing them to undergo surgery that may not otherwise be an option, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. (2014-09-16)

Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive. (2016-04-08)

Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award
Molecular biologist Jonathan Brody, Ph.D., assistant professor, department of surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network -- American Association of Cancer Research Career Development Award in memory of Skip Viragh. This two-year grant awards $200,000 to Dr. Brody to help support his innovative research in pancreatic cancer. He will receive recognition for his work at the 2010 AACR annual meeting in Washington, D.C., on April 20. (2010-04-13)

First feasibility study of the ESMO-MCBS scale in rare tumor entities
The results of the first study analysing the application of the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) in a real-life context for rare tumour entities, were announced today at the ESMO 2016 Congress in Copenhagen. (2016-10-10)

U of MN Cancer Center researchers testing new drug combination to treat lung cancer
University of Minnesota Cancer Center researchers are studying a new drug combination to treat patients with non-small cell lung cancer. Led by Arkadiusz Dudek, M.D., Ph.D., the researchers are evaluating whether the drug Thalidomide will help enhance the cancer-killing ability of two chemotherapy drugs. (2003-03-17)

Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness. (2017-07-12)

New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland. (2012-04-18)

UCLA scientists develop crystal ball for personalized cancer treatment
UCLA scientists have tested a non-invasive approach that may one day allow doctors to evaluate a tumor's response to a drug before prescribing therapy, enabling physicians to quickly pinpoint the most effective treatment and personalize it to the patient's unique biochemistry. The Proceedings of the National Academy of Sciences publishes the UCLA findings in its Feb. 2 advance online edition. (2009-02-02)

2 new therapies show promise for cancer patients
Clinical researchers at Scottsdale Healthcare and TGen today announced the results of two clinical trials that show promise for patients battling cancer. The Phase I clinical trial findings, presented at the this weeks Annual Meeting of the American Association for Cancer Research by Daniel Von Hoff, M.D., F.A.C.G., focused on basal cell carcinoma and pancreatic cancer. (2008-04-15)

Iniparib extends overall survival in metastatic triple-negative breast cancer
Women with an aggressive subtype of metastatic breast cancer appear to live an average of almost five months longer when treated with iniparib plus chemotherapy, compared to chemotherapy alone, the results of a randomized phase-II trial show (2010-10-10)

Erlotinib nearly triples progression-free survival compared with standard chemotherapy in patients with the most common form of lung cancer (OPTIMAL trial)
The targeted drug erlotinib nearly triples progression-free survival, and is better tolerated, compared with standard chemotherapy as the initial treatment for patients with advanced non-small-cell lung cancer whose tumors harbor epidermal growth factor receptor mutations. (2011-07-21)

Vitamin A may help improve pancreatic cancer chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London. The promising initial results have led to the potential treatment being tested in a new clinical trial. (2016-05-24)

Sortilin may hold the key to combat pancreatic cancer more effectively
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States. In a novel study published in The American Journal of Pathology, published by Elsevier, scientists report the discovery of an increased level of the neuroprotein sortilin in pancreatic cancer cells that may open up the way to developing more effective treatment. (2020-08-20)

2013 Gastrointestinal Cancers Symposium reveals new advances for GI cancers
New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held Jan. 24-26, 2013, at the Moscone West Building in San Francisco, Calif. (2013-01-22)

Stanford researchers develop new compound to reduce tumor growth
Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice. (2016-11-28)

Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe
Pembrolizumab, an immunotherapy drug that unmasks cancer cells and allows the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America at Western Regional Medical Center. Dr. Glen Weiss is the first author of the study abstract: Phase Ib/II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) one prior line of therapy. (2015-09-09)

Cell receptor may lead to new 'biomarker' for pancreatic cancer
A research team led by University of Cincinnati scientists has identified a potential biological target for pancreatic cancer, a finding they say could help scientists better understand -- and eventually treat -- the disease that kills more than 33,000 people each year. (2007-07-01)

Scientists identify aggressive pancreatic cancer cells and their vulnerability
A team from The University of Texas MD Anderson Cancer Center describes this week in the journal Nature a series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models that point to potential treatments for patients with a rapidly-progressing and resistant subgroup of tumor cells. (2017-02-09)

FDA approves new therapy for pancreatic cancer patients
Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde, that produced significant overall survival rates in an international clinical study conducted in part by researchers at HonorHealth Research Institute and the Translational Genomics Research Institute. (2015-10-26)

Response to preoperative therapy may predict survival in pancreatic cancer patients
New research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least. (2010-05-28)

A better way to personalize bladder cancer treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. In early proof-of-concept research, the team took bladder tumors from individual patients, identified actionable mutations and grafted the tumors into mice. (2015-08-13)

Double-agent chemotherapy gives survival benefit to patients over 70 with lung cancer, thus current monotherapy-only strategy should be revised
An article published online first by the Lancet concludes that, despite increased toxic effects, platinum-based doublet chemotherapy is associated with survival benefits compared with monotherapy in elderly patients with non-small-cell lung cancer, and thus the current treatment strategy for these patients (monotherapy only) should be reconsidered. (2011-08-08)

Disrupting the cellular process that promotes pancreatic cancer's deadly growth
Researchers say they've identified a way to disrupt a process that promotes the growth of pancreatic cancers -- one of the most difficult and deadly cancers to treat. (2020-12-08)

GOLFIG increased progression-free survival in colorectal cancer patients
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6. (2011-04-06)

TGen's Dr. Daniel Von Hoff delivers first Lori Groetken Memorial Lecture
Dr. Daniel Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute is the first recipient of the Lori Groetken Memorial Lecture and Award. Dr. Von Hoff's lecture, (2012-10-04)

Afatinib shows clinical benefit for lung cancer patients with brain metastases
Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI) afatinib compared to standard platinum doublet chemotherapy. (2016-01-25)

TGen Physician-in-Chief Dr. Daniel D. Von Hoff wins ASCO award
Dr. Daniel D. Von Hoff, physician-in-chief for the Translational Genomics Research Institute, has won a top award from the American Society of Clinical Oncology for his cancer research. (2010-04-01)

Clinical trial tests COXEN model to predict best treatment for bladder cancer
A computer model, COXEN, matches cancer genetics to best treatments. It is now in a national clinical trial for bladder cancer. (2014-08-13)

Celery, artichokes contain flavonoids that kill human pancreatic cancer cells
Celery, artichokes, and herbs, especially Mexican oregano, all contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells in the lab by inhibiting an important enzyme, according to two new University of Illinois studies. (2013-08-15)

Scientists show how molecular switch helps pancreatic cancer beat drugs
Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy. (2010-01-28)

Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer
Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for non-small lung cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer. (2010-04-26)

Page 5 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to